Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Lift Ban on Coadministration of Adrenalin Medications with Alpha-blocking Antipsychotic Drugs: MHLW Panel
March 19, 2018
- PMDA Estimates MID-NET Will Be Used for PMS for 18 Products Annually
March 16, 2018
- 3rd Batch of Sakigake Drugs to Be Announced Soon: MHLW Official
March 15, 2018
- MHLW Issues Safety Information with Special Feature on MID-NET Expected to Begin Full-Scale Operation on April 1
March 15, 2018
- PMDA’s Review Segment to Post Loss of around 500 Million Yen in FY2017; Ordinary Loss to Be Covered by Reserve Fund
March 14, 2018
- PMDA to Establish “Regulatory Science Center” in April to Deal with Advanced Science and Technology
March 14, 2018
- MHLW to Relax Regulatory Procedures to Prevent Discrepancies between Approved and Actual Manufacturing Practices
March 13, 2018
- Lexicon: G1/G2 Rule
March 9, 2018
- AMED Taking Applications for FY2018 CiCLE Grant Program, Will Make Final Selection by Early October
March 9, 2018
- Funding Disclosure Methods that Prohibit Printing Will Not Be Acceptable: MHLW Notifications on Clinical Research Law
March 9, 2018
- MHLW Proposes Working Group Discussions before Another Round of CEA Analyses for 7 Products: Chuikyo
March 8, 2018
- Kadcyla’s Premium Portion Cut by 90% on CEA, 1 Device Gets Upward Adjustment: Chuikyo
March 8, 2018
- Xofluza Subject to April Price Revision, but Will Maintain Full Price: MHLW Official
March 8, 2018
- Why Did Xarelto, Eliquis Lose PMP Eligibility?
March 7, 2018
- Xofluza to Join NHI Price List March 14 as Key Panel Gives Expedited OK
March 7, 2018
- 10 Billion Yen Could Be Saved If 80% Gx Use Achieved among Welfare Recipients: Govt
March 6, 2018
- New Authorized Generic Re-Pricing Rule Applied to Olmetec, Crestor AGs
March 6, 2018
- Rituxan Biosimilar Price Down 9.5% as Originator Hit by Re-Pricing
March 6, 2018
- Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
- Annual Savings from Use of Biosimilars Stands at Just 8.7 Billion Yen: MHLW
March 6, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…